Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncimmune Holdings plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Oncimmune
Z Score
Change To Inventory
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Cashflows From Investing Activities
Net Borrowings
Total Cashflows From Investing Activities
Change To Account Receivables
Change To Netincome
Change To Liabilities
Investments
Issuance Of Capital Stock
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Cash And Short Term Investments
Common Stock Total Equity
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Common Stock
Common Stock Shares Outstanding
Inventory
Short Term Debt
Net Tangible Assets
Long Term Debt
Net Receivables
Short Long Term Debt
Property Plant Equipment
Other Liab
Other Assets
Deferred Long Term Liab
Intangible Assets
Non Currrent Assets Other
Net Invested Capital
Non Current Liabilities Other
Net Working Capital
Capital Stock
Current Deferred Revenue
Capital Lease Obligations
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Net Income From Continuing Ops
Net Income Applicable To Common Shares
Tax Provision
Net Interest Income
Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
As of March 7, 2025, Net Invested Capital is expected to decline to about 2.3 M. The current year's Net Working Capital is expected to grow to about (699.4 K). At present, Oncimmune Holdings' Total Revenue is projected to increase significantly based on the last few years of reporting. The current year's Other Operating Expenses is expected to grow to about 7.4 M, whereas Selling General Administrative is forecasted to decline to about 1.9 M.
Oncimmune Holdings plc Company Z Score Analysis
Oncimmune Holdings' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Based on the company's disclosures, Oncimmune Holdings plc has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United Kingdom stocks is 100.0% higher than that of the company.
Did you try this?
Run ETFs Now
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
The Macroaxis Fundamental Analysis modules help investors analyze Oncimmune Holdings plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncimmune Holdings using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncimmune Holdings plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Oncimmune Holdings financial ratios help investors to determine whether Oncimmune Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oncimmune with respect to the benefits of owning Oncimmune Holdings security.